The verified answer
As of Oct 2026, DEPLOY verifies Intersect ENT: 1 model. 1 source back the record.
CategorySurgical robots
Overview
Intersect ENT is a medical device company specializing in ear, nose, and throat (ENT) implantable drug-delivery technology. Acquired by Medtronic in 2022.
Verified record
- Verified deployments
- None on file
- Active incidents
- None on file
Valuation of record
DEPLOY VERIFIEDAcquisitionAcquired by Medtronic
Key facts
HQ
Focus
Status
Data & sources
Web sources
1
1 source backing this record.View all →
Models (1)
View all models →Intersect ENT on the deployment map
View the global mapIntersect ENT has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.
No verified deployments for Intersect ENT on the DEPLOY record yet. Track Intersect ENT to know the moment the first one is verified.
Current leadership (1)
- Thomas West President and CEOsecondary-verified
Safety record
No incidents on record for Intersect ENT.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Recent coverage
Intersect ENT in third-party press
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
Financial state
- Reporting basis
- aggregator_estimate
- Lifecycle stage
- acquired
- Counterparty risk class
- moderate
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Acquisitions (1)
- acquired by Medtronicfull acquisition2021-08-01
Timeline
Every recorded move in Intersect ENT’s history, most recent first: funding rounds, partnerships, acquisitions, supply-chain starts, key hires, and press.
Acquired byAcquired by Medtronic
2021-08-01Acquired by Medtronic (full_acquisition)
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJun 25, 2026
Added to the verified registry
Sources (1)
Common questions
What is Intersect ENT?
What does Intersect ENT make?
Is Intersect ENT publicly traded?
Who competes with Intersect ENT?
Who is the CEO of Intersect ENT?
How can I invest in Intersect ENT?
Where is Intersect ENT headquartered?
Who owns Intersect ENT?
Where does Intersect ENT operate robots?
Is Intersect ENT a top robotics company?
Is Intersect ENT safe?
Methodology: Verified · 1 source (no primary) · last reviewed 2026-08-21
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-08-21
Sources by quality tier
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Intersect ENT.Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
In the press
Recent coverage mentioning Intersect ENT from third-party publications. Automatically surfaced; not part of the verified registry record.
Silk Road Medical names a new CEO - MassDevice
<a…
Medtronic completes Intersect ENT acquisition - MassDevice
<a…
Medtronic completes acquisition of Intersect ENT - PR Newswire
<a…
Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns - MassDevice
<a…
Medtronic completes Intersect acquisition following FTC order - MedTech Dive
<a…
Intersect ENT wins CE mark for Propel Contour sinus implant - MassDevice
<a…
Intersect ENT Announces FDA Approval Of PROPEL Contour, For Use In Treating The Frontal And Maxillary Sinuses - Medical Design & Outsourcing
<a…
Intersect ENT wins FDA nod for Propel Contour steroid-releasing implant - Drug Delivery Business
<a…
23 of the most powerful women engineers in the world - Business Insider
<a…
Machine-readable surfaces
- Markdown mirror: /companies/intersect-ent.md
- RSS feed: /companies/intersect-ent/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/169123ff-559d-4d05-a305-ac815ba31fc6
- Revision history: /companies/intersect-ent/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
Video
Intended for US Audiences Prescribing Information: http://www.SINUVA.com/PI What is SINUVA®? SINUVA Sinus Implant is a prescription steroid-releasing (mometasone furoate) implant indicated for the treatment of nasal
⚠️ Investors Deadline ⚠️ November 11, 2021 Click Here To Get Your Proof Of Claim Form ➡️ https://www.compensationrecovery.com/class-action/loss-submission/12796
Heat Index
Serious50/100
A composite of competitive footprint, funding, press velocity, active partnerships, and supply-chain edges. Different from the Intelligence score below (which is per-form-factor productization). Non-robotics companies cap at 25.
Reality vs attention
Intersect ENT draws attention at the 45th percentile but verifies reality at the insufficient-data level among surgical robots.
6-month trend
Analysis
Limited public funding data for capital position assessment.
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Oct 2, 2026